Gland Pharma Limited announced the outcome of its board meeting held on September 13, 2026, detailing the approval for acquiring 100% of the equity share capital of Gland Pharma USA Inc. (“Gland US”). Currently functioning as a wholly-owned step-down subsidiary, Gland US will become a direct wholly-owned subsidiary of the company upon completion of the transaction. The acquisition involves a cash consideration of USD 5,01,208 for 5,00,000 shares and is slated for completion by October 31, 2026.

The strategic rationale behind this corporate restructuring is to remove multiple operational layers and streamline the corporate hierarchy, with no material impact on the company’s core operations. Gland US, incorporated in March 2022, primarily engages in the marketing and distribution of pharmaceutical products within the United States. Because the target entity is a related party, the transaction has received prior approvals from the Audit Committee and Board of Directors on an arm’s length basis using valuations from an independent expert.

Gland Pharma Limited operates as a specialized contract development and manufacturing organization (CDMO) focusing primarily on complex injectables, sterile formulations, and biologicals. In recent 2025 developments, the company strengthened its market positioning by securing several key USFDA approvals for complex generic injectables and entering into strategic long-term sterile API partnerships. Operational updates also highlighted management changes, including leadership transitions aimed at optimizing global supply chain resilience and execution capabilities.

During the financial reporting periods of 2025, the company demonstrated steady revenue and profit recovery, driven by volume growth across key international markets like the US and Europe. Promoter activities during 2025 included strategic stake adjustments, notably when promoter Fosun Pharma offloaded a portion of its shareholding via open market transactions. Prominent institutional investors and mutual funds continue to hold significant stakes in the company, reflecting strong confidence in its complex injectables pipeline and long-term manufacturing growth visibility.